DNMT3B encodes a DNA methyltransferase implicated in aberrant epigenetic changes contributing to leukemogenesis. We tested whether DNMT3B expression, measured by NanoString nCounter assay, associates with outcome, gene and microRNA expression and DNA methylation profiles in 210 older (⩾60 years) adults with primary, cytogenetically normal acute myeloid leukemia (CN-AML). Patients were dichotomized into high versus low expressers using median cut. Outcomes were assessed in the context of known CN-AML prognosticators. Gene and microRNA expression, and DNA methylation profiles were analyzed using microarrays and MethylCap-sequencing, respectively. High DNMT3B expressers had fewer complete remissions (CR; P = 0.002) and shorter disease-free (DFS; P = 0.02) and overall (OS; P o 0.001) survival. In multivariable analyses, high DNMT3B expression remained an independent predictor of lower CR rates (P = 0.04) and shorter DFS (P = 0.04) and OS (P = 0.001). High DNMT3B expression associated with a gene expression profile comprising 363 genes involved in differentiation, proliferation and survival pathways, but with only four differentially expressed microRNAs (miR-133b, miR-148a, miR-122, miR-409-3p) and no differential DNA methylation regions. We conclude that high DNMT3B expression independently associates with adverse outcome in older CN-AML patients. Gene expression analyses suggest that DNMT3B is involved in the modulation of several genes, although the regulatory mechanisms remain to be investigated to devise therapeutic approaches specific for these patients.
INTRODUCTION
Acute myeloid leukemia (AML) is a heterogeneous disease presenting with a wide spectrum of prognostically relevant cytogenetic aberrations, gene mutations and abnormal expression of genes and microRNAs. Cytogenetically normal AML (CN-AML) patients, constituting 40 to 50% of all AML patients, 1 are the largest and molecularly best characterized cytogenetic subset in primary (de novo) AML. [1] [2] [3] Although leukemic blasts of these patients do not contain microscopically detectable chromosome abnormalities, they harbor prognostically relevant mutations and aberrantly expressed genes and microRNAs. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] In addition to these genetic alterations, epigenetic changes have recently been shown to participate in myeloid leukemogenesis and be pharmacologically targetable. 17, 18 Notably, some genes whose mutations are prognostic in CN-AML encode proteins that are implicated in epigenetic regulation of gene transcription, namely IDH2, ASXL1 and DNMT3A. The latter is among the most frequently mutated genes in primary CN-AML patients, being found mutated in 29 to 34% of the patients. 9, 19 DNMT3A encodes DNA methyltransferase 3A (DNMT3A), which is involved in epigenetic gene silencing through DNA hypermethylation. 20 In addition to DNMT3A, DNMT1 and DNMT3B also mediate DNA methylation in normal and malignant cells, and may represent potential therapeutic targets in cancer and leukemia. [21] [22] [23] [24] However, in contrast to DNMT3A, no recurrent mutations of DNMT1 and DNMT3B genes have been reported in AML. 25 Instead, one study has indicated that higher expression of DNMT3B is associated with worse outcome in AML. 26 However, the patient cohort analyzed was cytogenetically diverse and heterogeneous for clinical features and treatment received. Thus, it is unknown whether DNMT3B expression is an independent prognostic factor and can be used for stratification guidance in CN-AML.
Thus, we analyzed the clinical significance of DNMT3B expression in the context of a comprehensive panel of molecular prognosticators in a relatively large cohort of older (aged ⩾ 60 years) patients with CN-AML who were similarly treated on cytarabine/daunorubicin-based protocols. To gain biologic insights, we also derived genome-wide DNMT3B-associated gene and microRNA expression and DNA methylation profiles. We studied older patients because both the incidence of AML and the role of epigenetics increase with age. Moreover, we have recently reported a favorable clinical response to hypomethylating agents in this age group of AML patients. 27 
PATIENTS AND METHODS

Patients, treatment and cytogenetic studies
Pretreatment bone marrow or blood samples were obtained from 210 patients with primary CN-AML aged 60 to 83 years (median, 68 years) who received intensive first-line therapy on Cancer and Leukemia Group B (CALGB) trials. [28] [29] [30] [31] [32] All patients received cytarabine-daunorubicin-based induction chemotherapy, and no patient received allogeneic hematopoietic stem cell transplantation during first complete remission (CR). For details regarding treatment protocols and sample collection, see Supplementary Information. All patients were enrolled on companion CALGB/Alliance protocols: 8461 (cytogenetic analyses), 9665 (tissue banking) and 20 202 (molecular analyses).
Cytogenetic analyses were performed in institutional CALGB/Alliance cytogenetics laboratories. For the patient's karyotype to be considered normal, ⩾ 20 metaphase cells from short-term cultures of pretreatment bone marrow specimens had to have been analyzed and the normal result confirmed by central karyotype review. 33 All patients provided written informed consent for participation in these studies; study protocols were in accordance with the Declaration of Helsinki and approved by local Institutional Review Boards.
Single-gene expression analyses
The expression of DNMT3B transcript was assessed by NanoString nCounter assays (NanoString Technologies, Seattle, WA, USA; Supplementary Information). 34 These assays measured global expression of the DNMT3B gene, and did not allow for quantification of isoform-specific expression of DNMT3B. DNMT3B expression levels were normalized using ABL as an internal control. We also used NanoString nCounter assays to measure expression of BAALC, ERG and miR-155, and real-time reverse transcription-PCR to measure miR-3151 expression, all of which have been previously shown to affect prognosis of older CN-AML patients. 10, 15, 16 
Mutational analyses
The presence or absence of FLT3 internal tandem duplication (FLT3-ITD), 35, 36 FLT3 tyrosine kinase domain mutations (FLT3-TKD), 37 MLL partial tandem duplication (MLL-PTD), 38 Gene and microRNA expression profiling
The gene and microRNA expression profiling were assessed using the Affymetrix U133 plus 2.0 array (Affymetrix, Santa Clara, CA, USA) and The Ohio State University custom microRNA array (OSU_CCC Version 4.0, The Ohio State University, Columbus, OH, USA), respectively, as previously reported, 5, 43 and detailed in the Supplementary Information. For DNMT3B, the Affymetrix U133 plus 2.0 arrays measured global DNMT3B expression levels, and did not quantify expression of the individual DNMT3B isoforms. For the gene and microRNA expression profiling, summary measures of gene and microRNA expression were computed, normalized and filtered (Supplementary Information). A DNMT3B expression-associated signature (see Supplementary Information for details) was derived by comparing gene expression between high and low DNMT3B expressers in the CALGB/Alliance cohort and in two additional sets of CN-AML patients with microarray and RNAseq gene expression data publicly available (German AML Cooperative Group (AMLCG) 44 and The Cancer Genome Atlas (TCGA) 25 ). For comparison of the high DNMT3B expression signature with the FLT3-ITD signature we used gene set enrichment analysis (for details see Supplementary Information). For the microRNA expression signature, only the CALGB/Alliance patients were used. Univariable significance levels of Po0.001 (false discovery rates o0.01) were used to select genes and microRNAs that constituted the signatures. To assess enrichment of genes in the DNMT3B gene expressionassociated signature in distinct biologic processes, a Gene Ontology analysis was performed using the Database for Annotation, Visualization and Integrated Discovery (DAVID). 45 We identified as statistically significant 'annotation clusters' those clusters of Gene Ontology terms with enrichment scores of 42.0, P-values ⩽ 0.001 and Benjamini corrected P-values ⩽ 0.05. All molecular analyses were performed centrally at The Ohio State University.
DNA methylation
Genome-wide DNA methylation and levels of DNA methylation across the genome's functional regions (that is, genomic features) were measured using the MethylCap-seq assay as previously reported. 18 
Statistical analyses
The patients were dichotomized into high and low expressers using the median cut. This cut was supported by significant results of the trend test applied to outcome of patients divided into quartiles by DNMT3B expression (P ⩽ 0.001). We compared pretreatment features and outcome between patients with high and low DNMT3B expression. Definitions of clinical end points (that is, CR rates, disease-free (DFS) and overall (OS) survival) are provided in the Supplementary Information. Baseline characteristics between high and low DNMT3B expressers were compared using the Fisher's exact test for categorical and the Wilcoxon rank-sum test for continuous variables. 46 The categorical variables included the European LeukemiaNet (ELN) Genetic Groups. 47 The ELN guidelines classify CN-AML patients within the Favorable or Intermediate-I Genetic Groups based on CEBPA, NPM1 and FLT3 mutational status. The ELN Favorable Genetic Group consists of CN-AML patients with CEBPA mutation and/or NPM1 mutation without FLT3-ITD, whereas the Intermediate-I Genetic Group is comprised of patients with wild-type CEBPA and FLT3-ITD with or without NPM1 mutation, or wild-type NPM1 without FLT3-ITD.
47
For time-to-event analyses, we calculated survival estimates using the Kaplan-Meier method, and compared groups by the log rank test. 46 In order to provide the odds ratios and hazard ratios and associated confidence intervals, logistic regression and Cox proportional hazards models were generated to compare outcomes between high and low DNMT3B expressers for CR and survival end points (DFS, OS), respectively, and P-values from the Wald test are reported. We constructed multivariable logistic regression models to analyze factors associated with the achievement of CR, and multivariable Cox proportional hazards models for factors associated with survival end points, 46 the details of which are provided in the Supplementary Information. All analyses were performed by the Alliance for Clinical Trials in Oncology Statistics and Data Center.
RESULTS
Associations of DNMT3B expression with pretreatment clinical and molecular characteristics At diagnosis, high DNMT3B expressers had higher white blood counts (WBC; P = 0.004), and percentages of blood (P = 0.004) and marrow (P = 0.02) blasts than low DNMT3B expressers. Concerning molecular features, high DNMT3B expressers were more often FLT3-ITD-positive (P o0.001) and classified in the ELN Intermediate-I Genetic Group (P = 0.02). IDH2-R140 mutations were less frequent in high DNMT3B expressers, whereas six of seven IDH2-R172 mutations were detected in this patient group. High DNMT3B expressers also had higher ERG (P o0.001), BAALC (P = 0.002) and miR-155 (P = 0.006) expression than low expressers (Table 1 , Supplementary Figure S1 ).
Associations of DNMT3B expression with clinical outcome in the entire patient cohort With a median follow-up of 5.1 years (range, 2.3-11.6 years) for patients who are alive, high DNMT3B expressers had lower CR rates (P = 0.002, Wald test; 58% vs 78%), and shorter DFS (P = 0.02, Wald test) and OS (P o 0.001, Wald test) than DNMT3B low expressers (Table 2, Figure 1) . In a multivariable model for CR, DNMT3B expression remained prognostic (P = 0.04), after adjustment for BAALC expression status (P o 0.001), WBC (P = 0.007) and age (P = 0.02) ( Table 3) . High DNMT3B expressers were half as likely to achieve a CR as low expressers. In multivariable analysis for DFS, high DNMT3B expression associated with shorter DFS (P = 0.04), once adjusted for BAALC expression (P = 0.004), DNMT3A-R882 mutation status (P = 0.009) and ELN Genetic Groups (P = 0.03). The risk of experiencing relapse or death was 46% higher for high DNMT3B The ELN modified Favorable Genetic Group is defined as CN-AML patients with mutated CEBPA and/or mutated NPM1 without FLT3-ITD. All remaining CN-AML patients (that is, those with wild-type CEBPA and wild-type NPM1 with or without FLT3-ITD, or mutated NPM1 with FLT3-ITD) belong to the ELN Intermediate-I Genetic Group. 47 c The P-value pertains to a comparison of frequencies of IDH2-R140 mutations versus IDH2 wild-type between high and low DNMT3B expressers. The P-value pertains to a comparison of frequencies of IDH2-R172 mutations versus IDH2 wild-type between high and low DNMT3B expressers.
e The P-value pertains to a comparison of frequencies of DNMT3A-R882 mutations versus DNMT3A wild-type between high and low DNMT3B expressers. f The P-value pertains to a comparison of frequencies of DNMT3A non-R882 mutations versus DNMT3A wild-type between high and low DNMT3B expressers.
g The median expression value was used as a cut point.
h Data was assessed by the NanoString nCounter assay.
i Data was assessed by real-time reverse transcription-PCR.
DNMT3B expression in acute myeloid leukemia C Niederwieser et al expressers than for low expressers. DNMT3B expression also remained prognostic for OS (P = 0.001), after adjustment for BAALC (P o 0.001), miR-3151 (P = 0.02) and miR-155 (P = 0.02) expression. The risk of death was 72% higher for high DNMT3B expressers compared with low expressers (Table 3) .
Associations of DNMT3B expression with clinical outcome in ELN Genetic Groups We analyzed the associations of DNMT3B expression with outcome separately within the ELN Favorable and Intermediate-I Genetic Groups. Within the Favorable Group (n = 94), there was no significant difference in CR rates (71% vs 84%, P = 0.14, Wald test) or DFS (P = 0.10, Wald test) between high and low DNMT3B expressers. However, high expressers had shorter OS (P = 0.002, Wald test) than low expressers (Table 2 , Figures 2a and b) . In multivariable analyses for the ELN Favorable Genetic Group (Table 3) , DNMT3B expression remained significant for OS (P = 0.003) after adjustment for BAALC expression (P = 0.01). High DNMT3B expressers were twice as likely to die as low expressers.
In the Intermediate-I Group (n = 108), high DNMT3B expressers had a lower CR rate (49% vs 73%, P = 0.01, Wald test) and shorter OS (P = 0.03, Wald test) than low DNMT3B expressers, but there was no significant difference in DFS between the groups (Table 2 , Figures 2c and d) . In multivariable analyses within the ELN Intermediate-I Genetic Group (Table 3) , DNMT3B expression was significant for OS (P = 0.02), after adjustment for BAALC expression (P = 0.03), miR-3151 expression (P = 0.03) and WBC (P = 0.03). High DNMT3B expressers were 1.7 times more likely to die than low expressers.
Genome-wide gene expression profiles associated with DNMT3B expression To gain biologic insights into the role of DNMT3B, we derived a DNMT3B-associated gene expression profile using three independent sets of CN-AML patients, that is, CALGB/Alliance (n = 177), AMLCG (n = 75) and The Cancer Genome Atlas (n = 88). We identified 195 upregulated genes and 168 downregulated genes that were significantly associated with higher DNMT3B expression in each of the three cohorts (Supplementary Table S1 ). As high DNMT3B expression was associated with the presence of FLT3-ITD (Table 1) , we performed gene set enrichment analysis to test whether a set of 195 genes that are upregulated in high DNMT3B expressers was associated with a set of genes differentially expressed between patients who harbored FLT3-ITD versus those who did not (Supplementary Information). We found a significant correlation between the high DNMT3B expression and FLT3-ITD signatures (P = 0.006; false discovery rate = 0.006; Supplementary Figure S2 ). Among the genes upregulated in high DNMT3B expressers, we noted a variety of genes previously involved in AML including CDK6 and WT1 that encode cyclin kinase and transcription factor proteins, respectively. Among the downregulated genes, we noted genes involved with both normal Abbreviations: CI, confidence interval; ELN, European Leukemia Net; HR, hazard ratio; n, number; OR, odds ratio. a P-values provided are generated by logistic regression and Cox proportional hazards models to compare outcome of patients for CR and survival end points (DFS, OS), respectively, using the Wald test. The ELN modified Favorable Genetic Group is defined as CN-AML patients with mutated CEBPA and/or mutated NPM1 without FLT3-ITD. All remaining CN-AML patients (that is, those with wild-type CEBPA and wild-type NPM1 with or without FLT3-ITD, or mutated NPM1 with FLT3-ITD) belong to the ELN Intermediate-I Genetic Group. 47 monocyte/macrophage differentiation and immune function including CD14, TLR4, CEBPB and TLR8.
Gene Ontology was used to assess the biologic features of the DNMT3B expression profile (Table 4) . For DNMT3B-associated upregulated genes, there were three Gene Ontology terms comprising genes involved in nucleotide biosynthetic processes and metabolism and included in annotation cluster 1 that had a trend for statistical significance (Benjamini P-value o0.1). For DNMT3B-associated downregulated genes, cellular processes included lysosome biology, endocytosis and membrane signaling. These results may be interpreted as consistent with the previously noted dysregulated genes involved in monocyte/macrophage differentiation and activity.
Genome-wide microRNA profiles associated with DNMT3B expression The influence of DNMT3B expression on microRNA genome-wide profiles could be evaluated in 162 patients. In contrast to coding genes, only four microRNAs were differentially expressed between high and low DNMT3B expressers (P ⩽ 0.001). High DNMT3B expression was associated with miR-133b upregulation, and miR-148a, miR-122 and miR-409-3p downregulation. miR-133b upregulation in high DNMT3B expressers was somewhat surprising as this microRNA was reported to have tumor suppressor activity in other cancers. 48, 49 However, consistent with the downregulated gene expression profile as discussed above, miR-133b has recently been shown to target granulocyte-macrophage colonystimulating factor (GM-CSF), a cytokine involved in granulocytemonocyte/macrophage differentiation. 50 Among the downregulated microRNAs, miR-148a was reported to target DNMT3B and to be itself a target of aberrant hypermethylation in cancer. 51, 52 Lower expression of miR-122 has been associated with aggressive hepatocellular carcinoma and miR-409-3p with cell invasion and metastasis in gastric cancer [53] [54] [55] [56] ; however, a role for these microRNAs in AML is currently unknown.
Genome-wide methylation profiling associated with DNMT3B expression As DNMT3B encodes a methyltransferase that mediates de novo DNA methylation, we assessed whether high and low DNMT3B expressers differed in DNA methylation patterns. Surprisingly, we found no significant differences in genome-wide DNA methylation levels or in the numbers of differentially methylated regions 18 in distinct functional genomic regions (for example, gene promoters) when high versus low DNMT3B expressers were compared.
DISCUSSION
In this study, we report that high DNMT3B expression associates with lower CR rates and shorter DFS and OS in chemotherapytreated CN-AML patients aged ⩾ 60 years. High DNMT3B expression was associated with such adverse prognostic factors as FLT3-ITD, high ERG, BAALC and miR-155 expression and the ELN Intermediate-I Genetic Group; nevertheless the association of DNMT3B expression with clinical outcome is independent from the aforementioned and other established molecular and clinical prognosticators for all outcome end points studied.
Our findings are consistent to some extent with the only, to our knowledge, previous study that assessed the prognostic value of DNMT3B expression. 26 Although, in the subset of 93 CN-AML patients, Hayette et al. 26 did not find significant differences in event-free survival or OS between high and low DNMT3B expressers, high DNMT3B expressers had a shorter event-free survival than low DNMT3B expressers in the whole cytogenetically diverse cohort of 191 AML patients analyzed. It is difficult to directly compare their results with ours as approximately one-half of the patients analyzed by Hayette et al. 26 had various abnormal karyotypes, more than two-thirds of the patients were younger than 60 years and a quarter underwent allogeneic hematopoietic stem cell transplantation in first CR. Thus, although the two studies are not comparable, they both conclude that higher DNMT3B expression is associated with worse outcome in AML.
Recently, the ELN reporting system, 47 which for CN-AML is based on only three molecular markers (that is, FLT3-ITD, CEBPA and NPM1 mutations), was shown to provide important prognostic information in AML. 57 However, we and others have shown that additional molecular markers, such as TET2, 41 16 may refine outcome prediction of CN-AML patients within the ELN Genetic Groups. Hence, in the current study, we investigated whether considering DNMT3B expression as a novel prognosticator could alter patient classification within the ELN Genetic Groups. In the Favorable Group, we found that low DNMT3B expression identified a subset of CN-AML patients with a significantly longer OS, thus making DNMT3B expression the third molecular marker, in addition to ASXL1 mutations 8 and miR-155 expression, 15 capable of refining prognostication of older patients in this ELN Genetic Groups. We also observed a significant difference in OS between high and low DNMT3B expressers classified in the ELN Intermediate-I Genetic Group. Previously, RUNX1 mutations 42 and expression levels of MN1, 12 miR-155 15 and miR-3151 16 were demonstrated to add prognostic information in this ELN Genetic Group.
We report the first, to our knowledge, DNMT3B-associated gene and microRNA expression and DNA methylation profiles in CN-AML. We were able to derive a strong gene expression profile comprising 363 genes by overlapping the microarray results from three independent sets of patients. The profile was quite heterogeneous, comprising genes encoding for proteins involved in multiple biologic processes that play a role in leukemia cell differentiation, proliferation and survival. Among the downregulated genes, we noted enrichment of genes involved in monocyte/macrophage differentiation and activity, suggesting a role of DNMT3B in impairing differentiation of the leukemic blasts into cells with normal innate immunity activity. Using gene set enrichment analysis, we found a significant correlation between the high DNMT3B expression and FLT3-ITD signatures (Supplementary Figure S2) . This, along with the increased frequency of FLT3-ITD in high DNMT3B expressers (Table 1) , suggests the existence of a functional association between high expression of the DNMT3B gene and FLT3-ITD.
In contrast, the DNMT3B-associated microRNA profile was relatively weak, comprising only four microRNAs that were differentially expressed in high versus low DNMT3B expressers. Nevertheless, the unique upregulation of expression of miR-133b, recently reported to target GM-CSF, 50 in DNMT3B high expressers was somewhat consistent with the enrichment of the gene expression profile in multiple downregulated genes involved in the differentiation and activity of hematopoietic cells participating in innate immunity.
Surprisingly, despite the fact that DNMT3B encodes a DNA methyltransferase, we observed no significant association of high DNMT3B levels and DNA methylation changes. No difference in global DNA methylation levels and number of differentially methylated regions could be identified between DNMT3B high and low expressers. Our results are reminiscent of a recent report showing that changes in DNMT3B expression did not affect methylation levels of putative DNMT3B target genes. 59 Moreover, Russler-Germain et al. 60 have recently demonstrated that DNA methylation levels in leukemic blasts from CN-AML patients are not influenced by DNMT3B expression as mainly inactive splice variants of DNMT3B are expressed in these cells. Overall, therefore, these data may suggest that although overexpressed DNMT3B is a potentially valuable predictive marker for response to conventional chemotherapy, it does not necessarily identify subsets of older AML patients characterized by aberrant DNA methylation who might be responsive to hypomethylating azanucleosides.
In summary, we have demonstrated that DNMT3B expression constitutes an independent prognostic factor in older CN-AML patients treated intensively, and could also refine the ELN classification. Furthermore, we have provided some insights into the biologic activity of DNMT3B in CN-AML, which is seemingly independent from mechanisms of DNA hypermethylation and/or microRNA-dependent gene repression. Further studies focused on gaining more clinical and mechanistic insights into the leukemogenic role of DNMT3B expression are The types of DNMT3A mutations detected in our cohort are provided in Supplementary Table S2. b The ELN modified Favorable Genetic Group is defined as CN-AML patients with mutated CEBPA and/or mutated NPM1 without FLT3-ITD. All remaining CN-AML patients (that is, those with wild-type CEBPA and wild-type NPM1 with or without FLT3-ITD, or mutated NPM1 with FLT3-ITD) belong to the ELN Intermediate-I Genetic Group. 
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